Efficacy and Tolerability of Osmotic Release Oral System-Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder According to Comorbid Psychiatric Disorders.
- Author:
Hyung Jun YOON
1
;
Ki Hwan YOOK
;
Duk In JON
;
Jeong Ho SEOK
;
Narei HONG
;
Sung Shick CHO
;
Hyun Ju HONG
Author Information
1. Department of Psychiatry, Hallym University College of Medicine, Anyang, Korea. hongdr@chol.com
- Publication Type:Original Article
- Keywords:
ADHD;
OROS-Methylphenidate;
Comorbidity;
Efficacy;
Tolerability
- MeSH:
Aged;
Anxiety Disorders;
Attention Deficit and Disruptive Behavior Disorders;
Child;
Comorbidity;
Depressive Disorder;
Humans;
Outcome Assessment (Health Care);
Parents;
Patient Dropouts;
Tic Disorders;
Tics
- From:Journal of the Korean Academy of Child and Adolescent Psychiatry
2008;19(3):147-155
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The purpose of this study was to evaluate the efficacy and tolerability of osmotic release oral systemmethylphenidate (OROS-MPH) in children with attention-deficit hyperactivity disorder (ADHD) and comorbid psychiatric disorders. METHODS: This was an 8-week open label study of OROS-MPH monotherapy. The subjects were 113 children with ADHD aged 6-12 years. Outcome measures were the Korean version of the parent ADHD Rating Scale (K-ARS), Korean version of the Conners Parent Rating Scale (K-CPRS), Clinical Global Impression-Severity and Clinical Global Impression-Improvement. Side effects were monitored using Barkley's Side Effect Rating Scale. We compared the change-over-time in the mean scores of the outcome measure according to the comorbidity of disruptive behavior disorder, depressive disorder, anxiety disorder, and tic disorder. RESULTS: The mean K-ARS and K-CPRS scores were significantly decreased, regardless of the comorbidity. The mean doses of OROS-MPH and dropout rate did not differ significantly according to comorbidity. The OROS-MPH was well tolerated, regardless of the comorbidity. However, children with tic disorder reported a higher frequency of tics or nervous movements between the 2nd and 8th week than those without tic disorder. CONCLUSION: The OROS-MPH is effective for decreasing the symptoms of ADHD, and it is well tolerated, even by patients with comorbid psychiatric disorders.
